Papillary Epinephrine Injection Combined With Rectal Indomethacin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

504 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-01

Study Completion Date

2023-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most common and one of the most undesirable major adverse events after endoscopic retrograde cholangiopancreatography (ERCP), causing significant morbidity and even mortality. The incidence rate is almost 15% in high-risk patients and no less than 3% in average-risk patients.

Many factors contribute to PEP, such as patient-related and endoscopist-related factors, but mainly two mechanisms are considered in terms of physiopathology: papillary edema caused by mechanical trauma during cannulation and thermal injury with electrocautery current.

Rectal NSAIDs and pancreatic stent placement are the two proven methods of PEP prophylaxis that are included in the guideline recommendations, but despite the frequent use of these methods, the incidence rates are still more than acceptable. There is a need for additional methods that are easy to implement, preferably low cost, and safe to reduce the risk of PEP.

Topical epinephrine applied submucosally can be a method that meets these goals. Ampullary epinephrine injection is an effective method in terms of post sphincterotomy bleeding but to our knowledge, there is no study examining its efficacy in PEP prophylaxis except for one retrospective study that we reported.

There are conflicting reports on epinephrine spraying on the papilla in terms of PEP, but these trials are mostly heterogeneous with different dose regimens. It should also be noted that spraying epinephrine on the papilla has a length of action of about 1 to 5 minutes but the length of action for epinephrine injection is roughly 120 minutes.

Given this information, we designed a large-scale, double-blind, randomized, controlled, superiority trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal Indomethacin

NCT03057769

Pancreatitis Endoscopic Retrograde Cholangiopancreatography

TERMINATED NA

Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis

NCT01912716

Post-ERCP Pancreatitis

COMPLETED PHASE2/PHASE3

Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis

NCT03713879

Post ERCP Pancreatitis

RECRUITING PHASE3

Indomethacin Decreases Post-ERCP Pancreatitis

NCT02110810

Post ERCP Acute Pancreatitis

COMPLETED PHASE3

Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide

NCT03756116

Post-ERCP Acute Pancreatitis Epinephrine

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patient characteristics and procedure-related parameters will be recorded.

Patients will be divided into two as a patient group and a control group by 1:1 simple randomization. The patients in the indomethacin group will receive 100mg of rectal indomethacin alone, just before the procedure. In the combination group, the patients will receive 100mg of rectal indomethacin just before the procedure plus 4 quadrants of the peripapillary region will be injected with 1mL of undiluted epinephrine, 1 mL in each quadrant 1 to 2 cm away from the papillary orifice just before pulling out the duodenoscope.

The blood pressure, pulse rate, and electrocardiography will be monitored in all patients both during and after the procedure. All patients will be hospitalized for at least one night and the serum amylase and lipase levels will be measured before and again 4 hours after the procedures. Amylase, lipase, and other blood tests will also be performed routinely 24 hours after ERCP.

PEP was described as at least a threefold increase in amylase levels together with typical abdominal pain 24 hours after the procedure. Post-ERCP hyperamylasemia was defined using normal clinical conditions, but serum amylase levels were elevated above the normal upper limit (100 IU/L) 24 hours after the procedure. Patients at high risk for PEP and difficult cannulation were defined according to the European Society of Gastrointestinal Endoscopy Guidelines

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-ERCP Acute Pancreatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rectal indomethacin alone

All patients in this group receive preprocedural 100mg indomethacin spp

Group Type ACTIVE_COMPARATOR

Rectal indomethacin alone

Intervention Type DRUG

All patients in this group receive preprocedural 100mg indomethacin spp

Rectal indomethacin combined wit papillary epinephrine injection

All patients in this group receive preprocedural 100mg indomethacin spp and post-procedure 4 ml of undiluted epinephrine injected around the duodenal papilla on four quadrants, over a period of 60 seconds using a sclerotherapy needle

Group Type EXPERIMENTAL

Papillary epinephrine injection combined with rectal indomethacin

Intervention Type DRUG

All patients in this group receive preprocedural 100mg indomethacin spp and post-procedure 4 ml of undiluted epinephrine injected around the duodenal papilla on four quadrants, over a period of 60 seconds using a sclerotherapy needle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Papillary epinephrine injection combined with rectal indomethacin

All patients in this group receive preprocedural 100mg indomethacin spp and post-procedure 4 ml of undiluted epinephrine injected around the duodenal papilla on four quadrants, over a period of 60 seconds using a sclerotherapy needle

Intervention Type DRUG

Rectal indomethacin alone

All patients in this group receive preprocedural 100mg indomethacin spp

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PEI RI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who submitted a written informed consent for this trial, and aged between 18-80 years old
* Patients who have naïve papilla (no previous procedure was performed at ampulla)
* Patients who is suspected to have a biliary obstruction or biliary disease
* Patients who are needed to have endoscopic retrograde cholangiopancreatography for treatment of biliary obstruction

Exclusion Criteria

* Patients who are pregnant
* Patients with mental retardation
* Patients allergic to contrast agents
* Patients who received sphincterotomy or pancreatobiliary operation previously
* Patients who have ampulla of Vater cancer
* Patients who have difficulty with the approach to ampulla due to abdominal surgery including stomach cancer with Billroth II anastomosis
* Patients who have pancreatic diseases as below (at least one more);

* acute pancreatitis within 30days before enrollment
* idiopathic acute recurrent pancreatitis
* pancreas divisum
* obstructive chronic pancreatitis
* pancreatic cancer

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No